Compare TG Therapeutics Inc (TGTX) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vertiv Holdings Co — how do they compare? TG Therapeutics Inc trades at $49.7 (market cap $7.64B), while Vertiv Holdings Co trades at $295.06 (market cap $108.49B). The key difference: Vertiv Holdings Co is far larger — about 14.2× TG Therapeutics Inc's market cap, and Vertiv Holdings Co pays a 0.09% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | VRT | |
|---|---|---|
Market Cap | $7.64B | $108.49B |
Sector | Health | Technology |
52-Week High | $59.06 | $376.23 |
52-Week Low | $26.94 | $121.82 |
Enterprise Value | $7.84B | $108.72B |
Dividend Yield | — | 0.09% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
